Abstract 436P
Background
With the advent of personalized medicine, recent clinical trials have placed much emphasis on the OS and PFS of cancer patients. However, several international guidelines also emphasize the need for assessing the Health Related Quality of Life (HRQoL) as part of our holistic approach in the management of cancer patients. This study evaluated the present status of the Filipino oncologists’ approach in assessing the quality of life of cancer patients.
Methods
This was a cross-sectional study that utilized a survey questionnaire. Participants included physicians in the care of the cancer patient (consultants & trainees) – medical, surgical, radiation, gynecologic oncologists, and hematologists, who were contacted via email through the database of their respective societies, and personally during scientific meetings / conferences. Descriptive and multivariate analysis were used to analyze the data.
Results
312 oncologists participated. 96% reported that HQRoL assessment was important for clinical work, however 58% perceived HRQoL to be a vague term; 69% agreed that verbal HRQoL assessments were generally enough, and 39% reported that their patients did not accept HRQoL questionnaires. Furthermore, 78% did not know which HRQoL assessment tool to use, and that the questionnaires were too extensive and too lengthy for routine use; 55% reported that they did not feel sufficiently trained to assess HRQoL. About 89.42% reported that they will be more confident if local HRQoL assessment guidelines will be present, and 92.95% agreed to the use of a unified HRQoL assessment tool for Filipino cancer patients.
Conclusions
Filipino oncologists perceived HRQoL patient assessments to be important in clinical practice. However, majority did not know which tool to use and did not feel sufficiently trained to assess HRQoL. The creation of a practice guideline that would facilitate the use of a unified HRQoL assessment tool (containing 5-15 questions) for Filipino cancer patients will be explored.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - Genetic characteristics of participants in the Australian Pancreatic Screening Study
Presenter: Krithika Murali
Session: Poster display session
Resources:
Abstract
155P - Mean Platelet Volume (MPV) is it a new prognostic marker in resectable carcinoma stomach?
Presenter: Girish M. S
Session: Poster display session
Resources:
Abstract
156P - A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis
Presenter: Zhen Xiang
Session: Poster display session
Resources:
Abstract
157P - Lymph node ratio (LNR) a better prognostic factor after D2 gastrectomy
Presenter: Jitin Yadav
Session: Poster display session
Resources:
Abstract
158P - A clinical significance of preoperative C-reactive protein/albumin ratio in patients with extrahepatic bile duct cancer
Presenter: Kim Jinkook
Session: Poster display session
Resources:
Abstract
159P - The relation between obesity and cancer of gastrointestinal tract in Korea: The data from Statistic Korea between 2001 and 2016
Presenter: Hee Man Kim
Session: Poster display session
Resources:
Abstract
160P - Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
Presenter: Jooyoung Ha
Session: Poster display session
Resources:
Abstract
161P - Chitinase 3-Like 1 gene (T/C) polymorphism and serum YKL-40 in hepatocellular carcinoma
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
162P - Hypofractionated radiotherapy for pulmonary metastases from hepatocellular carcinoma: Treatment response and prognostic factors affecting survival
Presenter: In Young Jo
Session: Poster display session
Resources:
Abstract
163P - Excision repair cross-complementation group 1 and 2 (ERCC1/2) Single nucleotide polymorphisms and chemotherapy treatment outcome in Cholangiocarcinoma
Presenter: Thanachai Sanlung
Session: Poster display session
Resources:
Abstract